205- MacDonald J, McDonald J. Natalizumab for induction of remission in Crohn’s disease.
Cochrane Database Syst Rev. 2007;24:CD006097. - Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med.
2012;366:1870–80. - Colombel J-F, Sands BE, Rutgeerts P, Sandborn W, Danese S, D’Haens G, et al. The safety
of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2016;66(5):1–13. - Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, et al. The real-world effective-
ness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US
victory consortium. Am J Gastroenterol. 2016;111:1147–55. doi:10.1038/ajg.2016.236. - Khanna R, Preiss JC, MacDonald JK, Timmer A. Anti-IL-12/23p40 antibodies for induction
of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;11:CD007572. - Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao L, et al. O-001 a multicenter,
double- blind, placebo-controlled phase 3 study of Ustekinumab, a human IL-12/23P40 mAB,
in moderate-service Crohn’s disease refractory to anti-TNFα: UNITI-1. Inflamm Bowel Dis.
2016;22(Suppl 1):S1. - Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel C. Risks of serious infection or
lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease:
a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–51. - Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis.
2000;13:578–85. - Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly
is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis.
2009;15:182–9. - Bollegala N, Jackson TD, Nguyen GC. Increased postoperative mortality and complications
among elderly patients with inflammatory bowel diseases: an analysis of the national surgical
quality improvement program cohort. Clin Gastroenterol Hepatol. 2016;14:1274–81. - Beham AW, Puellmann K, Laird R, Fuchs T, Streich R, Breysach C, et al. A TNF-regulated
recombinatorial macrophage immune receptor implicated in granuloma formation in tuber-
culosis. PLoS Pathog. 2011;7:e1002375. - Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, et al.
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases:
consensus recommendations for infection reporting during clinical trials and postmarketing
surveillance. Ann Rheum Dis. 2015;74(12):1–10. - Centers for Disease Control and Prevention: TB risk factors. 2016. Cited 1 July 2016.
Available from: https://www.cdc.gov/tb/topic/basics/risk.htm. - Lee JW, Choi CH, Park JH, Kim JW, Kang SB, Koo JS, et al. Clinical features of active
tuberculosis that developed during anti-tumor necrosis factor therapy in patients with inflam-
matory bowel disease. Intest Res. 2016;14:146–51. - Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al.
Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent. N Engl
J Med. 2001;345:1098–104. - Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculo-
sis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble
tumor necrosis factor receptor therapy: the three-year prospective French research axed on
tolerance of biotherapies registry. Arthritis Rheum. 2009;60:1884–94. - Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific
risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy:
results from the British Society for Rheumatology biologics register (BSRBR). Ann Rheum
Dis. 2010;69:522–8. - Byun JM, Lee CK, Rhee SY, Kim H-J, Im JP, Park DI, et al. Risks for opportunistic tubercu-
losis infection in a cohort of 873 patients with inflammatory bowel disease receiving a tumor
necrosis factor-α inhibitor. Scand J Gastroenterol. 2015;50(3):312–20.
12 Infectious Complications of Biologics